The issues about chemoresistance in cervical cancer.

doi:10.7504/fk2015020104

Abstract

Abstract:

Abstract:Cervical cancer is the most common cancer in gynaecological carcinoma. To date, current approved managements continue to rely on the use of surgery, concurrent chemo-radiotherapy, and the chemotherapy is indispensable for high risk disease or metastatic, recurrent advanced lesions. But the chemoresistance hampers the efficacy of available anticancer drugs in treating cervical cancer. So searching biomarkers for predicting the chemosensitivity, explording sensitizer to increase the sensitivity to chemotherapy drugs, and studing new methods to reverse the chemoresistance and targeted-therapies will provide new approaches to the management of the chemoresistant cervical cancer.

Key words: cervical tumor, chemoresistance, chemotherapy sensitizer, targeted-therapy

摘要：

联合放疗和化疗的综合治疗是宫颈癌的主要治疗方法。化疗在宫颈癌高危病例和晚期复发转移患者的治疗中是必不可缺的重要手段。然而宫颈癌细胞对化疗药物产生的耐药性严重地影响了化疗药物的治疗效果。因此，探讨预测宫颈癌化疗敏感性的生物学指标，增强化疗药物敏感性，寻求逆转化疗耐药的新方法及靶向治疗将为宫颈癌化疗耐药的处理提供新的视角。

关键词: 宫颈肿瘤, 化疗耐药, 化疗增敏剂, 靶向治疗

CLC Number:

R737.3

LIU Hong,ZHANG Guo-nan.. The issues about chemoresistance in cervical cancer.[J]. Acta Metallurgica Sinica, DOI: 10.7504/fk2015020104.

刘红,张国楠. 宫颈癌化疗耐药相关问题[J]. 中国实用妇科与产科杂志, DOI: 10.7504/fk2015020104.

References

［1］   An JS, Huang MN, Song YM, et al. A preliminary study of genes related to concomitant chemoradiotherapy resistance in advanced uterine cervical squamous cell carcinoma［J］.Chin Med J (Engl)，2013，126(21):4109-4115.

［2］ Chen Y, Ke G, Han D, et al. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD［J］.Exp Cell Res，2014，320(1):12-20.

［3］ Okada T, Murata K, Hirose R, et al. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells［J］.Sci Rep，2013，3:2899.

［4］   Tai CJ, Wang JW, Su HY, et al. Glucose-regulated protein 94 modulates the therapeutic efficacy to taxane in cervical cancer cells［J］. Tumour Biol，2014 ，35(1):403-410.

［5］   Martinho O, Pinto F, Granja S, et al. RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy［J］.PLoS One，2013，8(3):e59104.

［6］   Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study［J］. J Clin Oncol，2009，27:1069-1074.

［7］ Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer［J］. J Clin Oncol，2010，28:3562-3569.

［8］ Yang Y, Zhao X, Chen W, et al. Effects of cidofovir on human papillomavirus-positive cervical cancer cells xenografts in nude mice［J］. Oncol Res，2010，18:519-527.

［9］ Kenter GG,Welters MJ,Valentijn AR，et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity［J］. Clin Cancer Res,2008, 14(1)：169-177.

［10］ Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer：preliminary results［J］.Med Oncol，2011，28(S1):540-546.

（2014-11-18收稿）

[1]	. [J]. Chinese Journal of Practical gynecology ang obstetric, 2022, 38(6): 628-633.
[2]	. [J]. Acta Metallurgica Sinica, 2021, 37(1): 18-24.
[3]	. [J]. Acta Metallurgica Sinica, 2021, 37(1): 15-17.
[4]	LIU Ping，LI Peng-fei. Standardized evaluation of cervical cancer patients before treatment. [J]. Acta Metallurgica Sinica, 2021, 37(1): 41-44.
[5]	HE Gui-fang，LING Bin. Standardization of preoperative adjuvant therapy for cervical cancer. [J]. Acta Metallurgica Sinica, 2021, 37(1): 44-48.
[6]	LU An-wei，ZHOU Li. Standardization of C1 radical hysterectomy for cervical cancer. [J]. Acta Metallurgica Sinica, 2021, 37(1): 48-51.
[7]	HUANG He，LIU Ji-hong. Standardization of postoperative adjuvant treatment for cervical cancer. [J]. Acta Metallurgica Sinica, 2021, 37(1): 51-54.
[8]	WU De-hua. Standardized radiotherapy for cervical cancer. [J]. Acta Metallurgica Sinica, 2021, 37(1): 54-59.
[9]	QU Qing-xi，ZHANG Shi-qian. Standardization of clinical research related to cervical cancer. [J]. Acta Metallurgica Sinica, 2021, 37(1): 59-63.
[10]	LIU Kai-jiang. Prevention and treatment of complications of radical hysterectomy. [J]. Acta Metallurgica Sinica, 2021, 37(1): 63-66.
[11]	LI Jin，WU Xiao-hua. Abdominal radical trachelectomy preserving fertility for ⅠB1 cervical cancer patients whose tumor ≥2cm：the evidence and controversy of "Fudan Criteria". [J]. Acta Metallurgica Sinica, 2019, 35(6): 614-618.
[12]	. [J]. Acta Metallurgica Sinica, 2019, 35(4): 424-430.
[13]	. [J]. Acta Metallurgica Sinica, 2019, 35(4): 435-437.
[14]	. [J]. Acta Metallurgica Sinica, 2019, 35(2): 188-193.
[15]	TANG Xiao-yan，QIU Jun-jun. Management of cervical cancer during pregnancy：current situation and the development. [J]. Acta Metallurgica Sinica, 2019, 35(10): 1085-1089.